FDA clearance can unlock the U.S. market. But does your current regulatory package support international expansion?
For U.S. medical device manufacturers, entering markets such as the European Union, Great Britain, Canada, Australia, Brazil, China, and selected Middle Eastern countries requires more than reusing an FDA submission. Differences in device classification, clinical evidence, technical documentation, testing, QMS requirements, labeling, UDI, local representation, registration ownership, and post-market obligations can create significant readiness gaps.
This Freyr white paper presents a practical framework for moving from FDA-cleared to global-market-ready. It explores FDA file reusability, market prioritization, clinical and technical documentation gaps, global core dossier development, labeling and UDI readiness, QMS alignment, local representation, hidden launch barriers, submission planning, and lifecycle governance.
Because FDA clearance is an important regulatory milestone. But sustainable global expansion requires a coordinated market access strategy.
Fill the form below to download the White Paper
